keyword
MENU ▼
Read by QxMD icon Read
search

Paritaprevir

keyword
https://www.readbyqxmd.com/read/28217256/interferon-free-regimens-in-patients-with-hepatitis-c-infection-and-renal-dysfunction-or-kidney-transplantation
#1
REVIEW
Evangelos Cholongitas, Chrysoula Pipili, George V Papatheodoridis
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given that ribavirin free regimens are preferable in CKD, elbasvir/grazoprevir is offered in CHC patients with genotype 1 or 4 and ombitasvir/paritaprevir and dasabuvir in genotype 1b for 12 wk. Although regimens containing peginterferon with or without ribavirin are officially recommended for patients with CKD and genotype 2, 3, 5, 6, such regimens are rarely used because of their low efficacy and the poor safety and tolerance profile...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28195877/direct-acting-antivirals-are-effective-for-chronic-hepatitis-c-treatment-in-elderly-patients-a-real-world-study-of-17%C3%A2-487-patients
#2
Feng Su, Lauren A Beste, Pamela K Green, Kristin Berry, George N Ioannou
BACKGROUND: The mean age of patients with chronic hepatitis C virus (HCV) infection in the USA has been increasing. Despite the increasing proportion of HCV-infected elderly patients, this group is under-represented in clinical trials of HCV treatment. AIM: We aimed to describe the real-world effectiveness of direct-acting antivirals (DAAs) among elderly patients. PATIENTS AND METHODS: We retrospectively identified 17 487 HCV-infected patients who were started on treatment with sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir-based regimens in the Veterans Affairs Healthcare System between 1 January 2014 and 30 June 2015...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28183063/real-life-experience-with-direct-acting-antivirals-agents-against-hepatitis-c-infection-in-elderly-patients
#3
Iria Rodríguez-Osorio, Purificación Cid, Luis Morano, Ángeles Castro, Marta Suárez, Manuel Delgado, Luis Margusino, Héctor Meijide, Berta Pernas, Andrés Tabernilla, José D Pedreira, Álvaro Mena, Eva Poveda
BACKGROUND: New direct-acting antivirals agents (DAAs) are very safe and well tolerated. OBJECTIVES: The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. STUDY DESIGN: All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October 2015). RESULTS: A total of 120 HCV mono-infected patients were recorded...
March 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28182216/ombitasvir-paritaprevir-ritonavir-and-dasabuvir-combination-treatment-in-patients-with-hiv-hcv-coinfection-results-of-an-italian-compassionate-use-program
#4
Massimo Andreoni, Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Andrea De Luca, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D'Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola Spinetti, Andrea Gori, Nicola Boffa, Bruno Cacopardo, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Daniela Segala, Loredana Sarmati
No abstract text is available yet for this article.
February 9, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28166520/universal-sustained-viral-response-to-the-combination-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-without-ribavirin-in-patients-on-hemodialysis-infected-with-hepatitis-c-virus-genotypes-1-and-4
#5
Soraya Abad, Almudena Vega, Eduardo Hernández, Evangelina Mérida, Patricia de Sequera, Marta Albalate, Nicolás Macías, Monica Milla, Juan M López-Gómez
BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent among patients on hemodialysis (HD) and is associated with poor prognosis. Treatment with interferon and ribavirin is poorly tolerated, and few data are available on the impact of new direct-acting antivirals (DAAs). This study was intended to analyze the efficacy and safety of treatment with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in HCV-infected patients on HD from 3 hospitals...
January 7, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28130599/progress-in-eradication-of-hcv-in-hiv-positive-patients-with-significant-liver-fibrosis-in-vienna
#6
Sebastian Steiner, Theresa Bucsics, Philipp Schwabl, Mattias Mandorfer, Bernhard Scheiner, Maximilian Christopher Aichelburg, Katharina Grabmeier-Pfistershammer, Peter Ferenci, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger
AIM: We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness. METHODS: In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed...
January 27, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28124463/hepatitis-c-treatment-from-response-guided-to-resource-guided-therapy-in-the-transition-era-from-ifn-containing-to-ifn-free-regimens
#7
REVIEW
Ming-Lung Yu
Peginterferon/ribavirin has been the standard-of-care for chronic hepatitis C virus (HCV) infections: 48-week for genotype 1 or 4 (HCV-1/4) and 24-week for HCV-2/3. Response-guided therapy recommended shorter 24-week and 16-week regimens for HCV-1 with lower baseline viral loads (LVL, <400,000-800,000 IU/ml) and rapid virological response (RVR, undetectable HCV RNA at week 4) and HCV-2/3 with RVR, respectively; and extending to 72 and 48 weeks for HCV-1 slower responders and HCV-2 non-RVR patients, respectively, to improve the efficacy...
January 26, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28101128/simultaneous-determination-of-newly-developed-antiviral-agents-in-pharmaceutical-formulations-by-hplc-dad
#8
Nourah Zoman Al-Zoman, Hadir Mohamed Maher, Amal Al-Subaie
BACKGROUND: Ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak(®)) are the newest medicines approved for use in the treatment of hepatitis C virus (HCV) and are available in tablet form as an oral combination. Specifically, these agents are indicated in the treatment of HCV in patients with genotype 1 infection. Due to the therapeutic importance and increased use of Viekira Pak, proper methods for its determination in bulk and pharmaceutical formulations must be developed. RESULTS: The present study describes the development and validation of a simple, rapid, selective and economical reverse phase high performance liquid chromatography-diode array detection (HPLC-DAD) method for the simultaneous determination of paritaprevir (PAR), ombitasvir (OMB), dasabuvir(DAS) and ritonavir (RIT) in bulk and pharmaceutical preparations...
2017: Chemistry Central Journal
https://www.readbyqxmd.com/read/28100444/successful-retreatment-of-a-patient-with-chronic-hepatitis-c-genotype-2k-1b-virus-with-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir
#9
Daniel Todt, Bernhard Schlevogt, Katja Deterding, Adam Grundhoff, Michael P Manns, Heiner Wedemeyer, Nicole Fischer, Markus Cornberg, Eike Steinmann
No abstract text is available yet for this article.
January 18, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28090038/combination-therapy-with-ombitasvir-paritaprevir-ritonavir-for-dialysis-patients-infected-with-hepatitis-c-virus-a-prospective-multi-institutional-study
#10
Ken Sato, Kenichi Hosonuma, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Hiroshi Ohnishi, Hiroaki Okamoto, Masanobu Yamada
Hepatitis C virus (HCV) infection is common in dialysis patients worldwide and nosocomial HCV spread within dialysis facilities continues to develop. Combination therapy with daclatasvir and asunaprevir (DCV/ASV) that has proven efficacy for dialysis patients infected with genotype 1b HCV (HCV/1b) has several concerns in Japan. The recently available combination therapy with ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r) is not contraindicated in patients with chronic renal failure and has more safety profile and shorter treatment period than that with DCV/ASV...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28052633/hepatitis-c-efficacy-and-safety-in-real-life
#11
REVIEW
Robert Flisiak, Joanna Pogorzelska, Marta Flisiak-Jackiewicz
Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28025084/a-profiling-study-of-a-newly-developed-hcvcc-strain-pr63cc-s-sensitivity-to-direct-acting-antivirals
#12
Wanyin Tao, Tianyu Gan, Jie Lu, Jin Zhong
The development of direct-acting antivirals (DAAs) has significantly improved hepatitis C virus (HCV) treatment. However, drug resistance remains a potential concern in the real-world DAA-based therapies. We previously developed a novel full-length genotype 2a HCVcc clone PR63cc directly from clinical isolates. Here in this study, we compared the sensitivity of PR63cc and JFH1 to 12 different DAAs most of which are either already in clinical use or in the late clinical development phase. For NS5B inhibitors, PR63cc and JFH1 displayed comparable sensitivity to nucleoside/nucleotide analogues sofosbuvir and 2'-C-methyladenosine, while PR63cc was 4-fold more sensitive than JFH1 to nesbuvir, a non-nucleoside inhibitor...
December 23, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28018873/restrictions-for-reimbursement-of-direct-acting-antiviral-treatment-for-hepatitis-c-virus-infection-in-canada-a-descriptive-study
#13
Alison D Marshall, Sahar Saeed, Lisa Barrett, Curtis L Cooper, Carla Treloar, Julie Bruneau, Jordan J Feld, Lesley Gallagher, Marina B Klein, Mel Krajden, Naglaa H Shoukry, Lynn E Taylor, Jason Grebely
BACKGROUND: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada. METHODS: We reviewed the reimbursement criteria for simeprevir, sofosbuvir, ledipasvir-sofosbuvir and paritaprevir-ritonavir-ombitasvir plus dasabuvir in the 10 provinces and 3 territories...
October 2016: CMAJ Open
https://www.readbyqxmd.com/read/28011605/ombitasvir-paritaprevir-ritonavir-and-dasabuvir-combination-treatment-in-patients-with-hiv-hcv-co-infection-results-of-an-italian-compassionate-use-program
#14
Andreoni Massimo, Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Andrea De Luca, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D'Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola Spinetti, Andrea Gori, Nicola Boffa, Cacopardo Bruno, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Daniela Segala, Loredana Sarmati
Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
December 22, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27981315/a-case-of-acute-liver-failure-during-ritonavir-boosted-paritaprevir-ombitasvir-and-dasabuvir-therapy-in-a-patient-with-hcv-genotype-1b-cirrhosis
#15
Marco Masetti, Donatella Magalotti, Elena Martino, Pietro Andreone, Alessandra Scuteri, Marco Zoli
BACKGROUND: Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin is one of the current recommended therapies for HCV genotype 1b monoinfected patients in compensated (Child-Pugh A) cirrhosis. Whether it is known that the worsening of liver function is a rare but possible complication of Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir therapy, to our knowledge no description of treatment-related acute liver failure is available in the literature. CASE PRESENTATION: An 84-year-old Caucasian man with chronic compensated HCV genotype 1b cirrhosis received Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy...
December 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/27976491/effectiveness-and-safety-of-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-an-early-access-programme-for-spanish-patients-with-genotype-1-4-chronic-hepatitis-c-virus-infection
#16
C Perelló, J A Carrión, B Ruiz-Antorán, J Crespo, J Turnes, J Llaneras, S Lens, M Delgado, J García-Samaniego, F García-Paredes, I Fernández, R M Morillas, D Rincón, J C Porres, M Prieto, M Lázaro Ríos, C Fernández-Rodríguez, J A Hermo, M Rodríguez, J I Herrero, P Ruiz, J R Fernández, M Macías, J M Pascasio, J M Moreno, M Á Serra, J Arenas, Y Real, F Jorquera, J L Calleja
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naïve and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65...
March 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27976490/therapy-with-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-is-effective-and-safe-for-the-treatment-of-genotype-1-and-4-hepatitis-c-virus-infection-hcv-in-patients-with-severe-renal-impairment-a-multicenter-experience
#17
Raquel Muñoz-Gómez, Diego Rincón, Adriana Ahumada, Eduardo Hernández, María José Devesa, Sonia Izquierdo, Maria Ortiz, Alicia Hernández-Albujar, Conrado Fernández-Rodríguez, Marta Calvo, Rosario González, Mar Lozano, Gregorio Castellano, Inmaculada Fernández-Vázquez
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15-29 mL/min/1...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27971346/the-benefits-of-earlier-treatment-with-paritaprevir-rotanavir-ombitasvir-with-or-without-dasabuvir-in-ireland
#18
R Baj, J Kavanagh, M O'Meara, C McKinley
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971322/health-economic-evaluation-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-for-treatment-of-chronic-genotype-1-hcv-infection-in-germany
#19
G Sroczynski, A Conrads-Frank, F Kühne, N Mühlberger, H Fröhlich, B Dietz, J C Samp, S Zeuzem, U Siebert
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971320/cost-effectiveness-of-paritaprevir-rotanavir-ombitasvir-with-or-without-dasabuvir-in-ireland
#20
R Baj, J Kavanagh, K M Egan, C McKinley
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
59050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"